Co-formulation with GLP-1 or SGLT2 inhibitors has the potential to reduce required doses, improve tolerability, and more effectively address the multifactorial nature of T2D compared to monotherapy. The gene discussed is GCG; the disease is type 2 diabetes mellitus.